Implications of nonuniform tumor doses for radioimmunotherapy

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1337-1341

  O'Donoghue, Joseph A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Combined modalities; Fractionation; Heterogeneity; Linear quadratic model; Nonuniform dosimetry

Indexed keywords

ARTICLE; DOSE RESPONSE; MATHEMATICAL MODEL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; TUMOR;

DRUG ADMINISTRATION SCHEDULE; MODELS, BIOLOGICAL; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY;

EID: 0032819736     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
2. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
3. 131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma. Eur J Pediatr Surg. 1996;6:155-158.
4. Crippa F, Bolis G, Seregni E, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686-690.
5. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68:403-406.
6. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11:1699-1707.
7. Deacon JM, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol. 1984;2:317-323.
8. Rubin P, Siemann DW. Principles of radiation oncology and cancer radiotherapy. In: Rubin P, ed. Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. 7th ed. Philadelphia, PA: WB Saunders; 1993:71-90.
9. Mariani G. Cei A, Collecchi P, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125] iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993;34:1175-1183.
10. Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. A quantitative study of metaiodobenzylguanidine (MIBG) uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med. 1989;30:474-480.
11. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11:738-750.
12. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75-83.
13. Humm JL. Problems and advances in the dosimetry of radionuclide targeted therapy. Recent Results Cancer Res. 1996;141:37-65.
14. O'Donoghue JA. Optimal scheduling of combined biologically targeted radio-therapy and total body irradiation with bone marrow rescue for the treatment of systemic malignant disease. Int J Radiat Oncol Biol Phys. 1991;21:1587-1594.
15. O'Donoghue JA. Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res. 1996;141:77-99.
16. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using auger electron emitters. Phys Med Biol. 1996;41:1973-1992.
17. 131iodine-labeled antibody for a colon cancer model. Cancer Res. 1995;55(suppl):5811s-5816s.
18. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24:103-110.
19. Barendsen GW. Dose fractionation, dose-rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981-1997.
20. Thames HD, Peters LJ, Withers HR, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationships. Int J Radiat Oncol Biol Phys. 1982;8:219-226.
21. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515-528.
22. Fowler JF. Radiobiological aspects of low dose-rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1261-1269.
23. Wheldon TE, O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radiat Biol. 1990;58:1-21.
24. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol. 1991;64:242-251.
25. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
26. Lee SP, Leu MY, Smathers JB, McBride WH, Parker RG, Withers HR. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys. 1995;33:375-389.
27. Wheldon TE, Deehan C, Wheldon EG, Barrett A. The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol. 1998;46:285-295.
28. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.
29. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82: 763-771.
30. 131I-labeled monoclonal antibody CC49. Cancer Res. 1995:55(suppl):5881s-5887s.
31. Sun LQ, Vogel CA, Mirimanoff RO, et al. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res. 1997;57:1312-1319.
32. Buchegger F, Rojas A, Delaloye AB, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res. 1995;55:83-89.
33. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997;57:447-453.